Advertisement

Cancer Causes & Control

, Volume 23, Issue 9, pp 1549–1555 | Cite as

DNA methyltransferase 3b (DNMT3b), tumor tissue DNA methylation, Gleason score, and prostate cancer mortality: investigating causal relationships

  • Anna Gillio-TosEmail author
  • Valentina Fiano
  • Daniela Zugna
  • Loredana Vizzini
  • Neil Pearce
  • Luisa Delsedime
  • Franco Merletti
  • Lorenzo Richiardi
Original paper

Abstract

Purpose

Aberrant DNA methylation plays a role in prostate cancer progression. We studied the relationships among DNA methyltransferase (DNMT) genotype, DNA methylation, Gleason score, and mortality in two cohorts of prostate cancer patients, previously reported with associations between DNA methylation in GSTP1, APC, and RUNX3 and prostate cancer mortality. Herein, we considered possible causal relationships between the studied variables, assuming that (1) DNMT activity affects tumor tissue methylation, (2) methylation status affects tumor morphology, and thus the Gleason score, and (3) DNA methylation affects mortality via Gleason score.

Methods

The cohorts comprised 438 patients diagnosed at one Italian pathology ward before 1997, with DNA obtained from paraffin-embedded tumor tissues. The polymorphism rs406193 in the DNMT3b gene was assessed by allele discrimination in real-time PCR. According to the assumed causal model, we analyzed the effects of rs406193 (T carriers vs others) on the Gleason score without adjusting for gene methylation, and the effects of rs406193 on gene methylation and prostate cancer mortality without adjusting for Gleason score.

Results

We found no evidence of association between T carriers and the number of methylated genes. However, T carriers had reduced risk of a Gleason score 8+ (odds ratio = 0.57, 95 % CI 0.39–0.85), and a hazard ratio of 0.81 (0.61–1.09) of dying from prostate cancer, which would have been erroneously estimated of 0.93 if adjusted for Gleason score.

Conclusions

These findings provide clues on the role of a DNMT3b SNP in prostate cancer progression and illustrate the importance of considering possible causal relationships in the analyses.

Keywords

DNA methylation DNA methyltransferase 3b Prostate cancer Gleason score Mortality Causal relationship 

Notes

Acknowledgments

The study was supported by the Italian Association for Research on Cancer (AIRC), the Compagnia San Paolo/Firms and the Piedmont Region. The research leading to these results has also received funding from the EU 7th Framework Programme under grant agreement number 247642, GEoCoDE. The work of Loredana Vizzini was partially supported by the Master in Epidemiology, University of Turin and Compagnia di San Paolo. The Centre for Public Health Research is supported by a Programme Grant from the Health Research Council of New Zealand.

Conflict of interest

No potential conflict of interest was disclosed.

References

  1. 1.
    Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 27:457–463CrossRefGoogle Scholar
  2. 2.
    Esteller M (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16(Spec No 1):R50–R59PubMedCrossRefGoogle Scholar
  3. 3.
    Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG (2004) Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 46:698–708PubMedCrossRefGoogle Scholar
  4. 4.
    Park JY (2010) Promoter hypermethylation in prostate cancer. Cancer Control 17:245–255PubMedGoogle Scholar
  5. 5.
    Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O, Gillio-Tos A, Merletti F (2009) Promoter methylation in APC, RUNX3 and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 27:3161–3168PubMedCrossRefGoogle Scholar
  6. 6.
    Jones PA, Liang G (2009) Rethinking how DNA methylation patterns are maintained. Nat Rev Gene 10:805–811CrossRefGoogle Scholar
  7. 7.
    Ezzikouri S, El Feydi AE, Benazzouz M, Afifi R, El Kihal L, Hassar M, Akil A, Pineau P, Benjelloun S (2009) Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol 9:877–881PubMedCrossRefGoogle Scholar
  8. 8.
    Jones JS, Amos CI, Pande M, Gu X, Chen J, Campos IM, Wei Q, Rodriguez-Bigas M, Lynch PM, Frazier ML (2006) DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev 15:886–891PubMedCrossRefGoogle Scholar
  9. 9.
    Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, Smith PL, Conroy D, Luben R, Perkins B, Easton DF, Dunning AM, Esteller M, Ponder BA (2006) Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 27:1661–1669PubMedCrossRefGoogle Scholar
  10. 10.
    Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q (2002) A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res 6:4992–4995Google Scholar
  11. 11.
    Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, Lee BH, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Cho YL, Jung TH, Park JY (2005) DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 26:403–409PubMedCrossRefGoogle Scholar
  12. 12.
    Montgomery KG, Liu MC, Eccles DM, Campbell IG (2004) The DNMT3B C → T promoter polymorphism and risk of breast cancer in a British population: a case-control study. Breast Cancer Res 6:R390–R394PubMedCrossRefGoogle Scholar
  13. 13.
    Singal R, Das PM, Manoharan M, Reis IM, Schlesselman JJ (2005) Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep 14:569–573PubMedGoogle Scholar
  14. 14.
    Fan H, Zhang F, Hu J, Liu D, Zhao Z (2008) Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case-control study. J Exp Clin Cancer Res 27:24PubMedCrossRefGoogle Scholar
  15. 15.
    de Vogel S, Wouters KA, Gottschalk RW, van Scooten FJ, de Goeij AF, de Bruine AP, Goldbohm RA, van den Brandt PA, Weijenberg MP, van Engeland M (2009) Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev 18:3086–3096PubMedCrossRefGoogle Scholar
  16. 16.
    Feuer EJ, Merrill RM, Hankey BF (1999) Cancer surveillance series: interpreting trends in prostate cancer–part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91:1025–1032PubMedCrossRefGoogle Scholar
  17. 17.
    Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. JASA 94:496–509Google Scholar
  18. 18.
    Petersen M, Sinisi S, van der Laan M (2006) Estimation of direct causal effects. Epidemiology 17:276–284PubMedCrossRefGoogle Scholar
  19. 19.
    Martin NE, Mucci LA, Loda M, Depinho RA (2011) Prognostic determinants in prostate cancer. Cancer J 17:429–437PubMedCrossRefGoogle Scholar
  20. 20.
    Kulis M, Esteller M (2010) DNA methylation and cancer. Adv Genet 70:27–56PubMedCrossRefGoogle Scholar
  21. 21.
    Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J, Kim DH (2006) Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary non small cell lung cancer. Cancer 107:1042–1049PubMedCrossRefGoogle Scholar
  22. 22.
    Xing J, Stewart DJ, Gu J, Lu C, Spitz MR, Wu X (2008) Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer 98:1716–1722PubMedCrossRefGoogle Scholar
  23. 23.
    Liu Z, Wang L, Wang LE, Sturgis EM, Wei Q (2008) Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 268:158–165PubMedCrossRefGoogle Scholar
  24. 24.
    Wang L, Rodriguez M, Kim ES, Xu Y, Bekele N, El-Naggar AK, Hong WK, Mao L, Oh YW (2004) A novel C/T polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer. Int J Oncol 25:993–999PubMedGoogle Scholar
  25. 25.
    Wu Y, Lin JS (2007) DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a case-control study. World J Gastroenterol 13:6082–6086PubMedCrossRefGoogle Scholar
  26. 26.
    Aung PP, Matsumura S, Kuraoka K, Kunimitsu K, Yoshida K, Matsusaki K, Nakayama H, Yasui W (2005) No evidence of correlation between the single nucleotide polymorphism of DNMT3B promoter and gastric cancer risk in a Japanese population. Oncol Rep 14:1151–1154PubMedGoogle Scholar
  27. 27.
    Kaufman JS, Maclehose RF, Kaufman S (2004) A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. Epidemiol Perspect Innov I:4CrossRefGoogle Scholar
  28. 28.
    Troyer DA, Lucia MS, de Bruïne AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW (2009) Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev 18:2717–2722PubMedCrossRefGoogle Scholar
  29. 29.
    Relton CL, Davey Smith G (2010) Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment. PLoS Med 7:e1000356PubMedCrossRefGoogle Scholar
  30. 30.
    Jurkowska RZ, Jurkowski TP, Jeltsch A (2011) Structure and function of mammalian DNA methyltransferases. ChemBioChem 12:206–222PubMedCrossRefGoogle Scholar
  31. 31.
    Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C (2007) Cancer genetics of epigenetic genes. Hum Mol Genet 16(Spec No 1):R28–R49PubMedCrossRefGoogle Scholar
  32. 32.
    Phé V, Cussenot O, Rouprêt M (2010) Methylated genes as potential biomarkers in prostate cancer. BJU Int 105:1364–1370PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Anna Gillio-Tos
    • 1
    Email author
  • Valentina Fiano
    • 1
  • Daniela Zugna
    • 1
  • Loredana Vizzini
    • 1
  • Neil Pearce
    • 3
    • 4
  • Luisa Delsedime
    • 2
  • Franco Merletti
    • 1
    • 3
  • Lorenzo Richiardi
    • 1
    • 3
  1. 1.Cancer Epidemiology Unit, CERMS and CPO-PiemonteUniversity of TurinTurinItaly
  2. 2.Department of PathologyMolinette HospitalTurinItaly
  3. 3.Centre for Public Health ResearchMassey UniversityWellingtonNew Zealand
  4. 4.Faculty of Epidemiology and Public HealthLondon School of Hygiene and Tropical MedicineLondonUK

Personalised recommendations